Literature DB >> 7091749

Halothane biotransformation in obese and nonobese patients.

J B Bentley, R W Vaughan, A J Gandolfi, R C Cork.   

Abstract

Serum levels of inorganic fluoride, trifluoroacetic acid, and bromide ion were measured at various time intervals following two hours of halothane anesthesia in 17 morbidly obese and eight nonobese patients. Ionic fluoride, a marker of reductive halothane metabolism, increased in the obese but not the nonobese patients. This is of concern since reductive halothane metabolism is associated with hepatoxicity in animals. In addition, serum bromide levels were higher after 48 h in the obese patients compared to the nonobese patients (mean +/- SE, 1,311 +/- 114 vs. 787 +/- 115 microM, P less than 0.01). Sedative levels of bromide were not attained in any patient. Peak trifluoroacetic acid levels were similar in the two patient groups. Sex age, medication intake, and smoking history had no influence on the halothane metabolite levels found in this study.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7091749     DOI: 10.1097/00000542-198208000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

3.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

Review 4.  Toxicity of inhaled agents after prolonged administration.

Authors:  Panumart Manatpon; W Andrew Kofke
Journal:  J Clin Monit Comput       Date:  2017-11-02       Impact factor: 2.502

Review 5.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Halothane hepatitis in Iran: a review of 59 cases.

Authors:  Payam Eghtesadi-Araghi; Amirali Sohrabpour; Homayoon Vahedi; Mehdi Saberi-Firoozi
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

7.  Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia.

Authors:  Y Tohyama
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

8.  Effects of tail fat on recovery times of anesthesia with isoflurane in fat-tailed Iranian Lori-Bakhtiyari lambs.

Authors:  Siavash Sharifi; Abbas Raisi Sarteshnizi; Farangis Sharifi; Elham Yousefian
Journal:  Vet Res Forum       Date:  2015-09-15       Impact factor: 1.054

9.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.